Corcept Therapeutics Incorporated (0I3Q.L)
USD 55.58
(-0.47%)
USD 55.58
(-0.47%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 482.37 Million | 401.85 Million | 365.97 Million | 353.87 Million | 306.48 Million | 251.24 Million |
| Cost of Revenue | 6.48 Million | 5.38 Million | 5.28 Million | 5.58 Million | 5.5 Million | 5.21 Million |
| Gross Profit | 475.89 Million | 396.47 Million | 360.69 Million | 348.29 Million | 300.98 Million | 246.03 Million |
| Operating Expenses | 368.61 Million | 283.83 Million | 236.22 Million | 220.09 Million | 189.37 Million | 156.53 Million |
| Selling, General and Administrative Expenses | 184.25 Million | 152.84 Million | 122.35 Million | 105.32 Million | 100.35 Million | 81.28 Million |
| Research and Development Expenses | 184.35 Million | 130.99 Million | 113.86 Million | 114.76 Million | 89.01 Million | 75.24 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 375.09 Million | 289.22 Million | 241.5 Million | 225.67 Million | 194.88 Million | 161.75 Million |
| Operating Income | 107.28 Million | 112.63 Million | 124.47 Million | 128.2 Million | 111.6 Million | 89.49 Million |
| Interest Expense | - | 3.55 Million | - | - | 5.07 Million | 2.65 Million |
| Income Tax Expense | 18.41 Million | 14.77 Million | 12.49 Million | 25.59 Million | 22.49 Million | 16.74 Million |
| Earnings before Tax | 124.55 Million | 116.19 Million | 125 Million | 131.6 Million | 116.67 Million | 92.15 Million |
| Net Income | 106.14 Million | 101.41 Million | 112.51 Million | 106.01 Million | 94.18 Million | 75.41 Million |
| Earnings Per Share Basic | 1.02 | 0.95 | 0.97 | 0.92 | 0.82 | 0.60 |
| Earnings Per Share Diluted | 0.94 | 0.87 | 0.89 | 0.85 | 0.77 | 0.60 |
| Weighted Average Shares Outstanding | 103.56 Million | 106.78 Million | 115.65 Million | 115.41 Million | 114.34 Million | 125.68 Million |
| Weighted Average Shares Outstanding (Diluted) | 111.74 Million | 115.96 Million | 125.96 Million | 124.19 Million | 122.56 Million | 126.68 Million |
| Gross Margin | 0.99 | 0.99 | 0.99 | 0.98 | 0.98 | 0.98 |
| EBIT Margin | 0.22 | 0.28 | 0.34 | 0.36 | 0.36 | 0.36 |
| Profit Margin | 0.22 | 0.25 | 0.31 | 0.30 | 0.31 | 0.30 |
| EBITDA | 108.32 Million | 112.63 Million | 124.47 Million | 130.43 Million | 113.77 Million | 89.73 Million |
| Earnings Before Tax Margin | 0.22 | 0.28 | 0.34 | 0.36 | 0.36 | 0.36 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 182.54 Million | 163.79 Million | 146.8 Million | 135.4 Million | 482.37 Million | 123.6 Million |
| Cost of Revenue | 2.86 Million | 2.52 Million | 2.53 Million | 1.87 Million | 6.48 Million | 1.64 Million |
| Gross Profit | 179.67 Million | 161.27 Million | 144.27 Million | 133.52 Million | 475.89 Million | 121.95 Million |
| Operating Expenses | 133.08 Million | 125.68 Million | 114.77 Million | 101.85 Million | 368.61 Million | 90.77 Million |
| Selling, General and Administrative Expenses | 73.74 Million | 66.93 Million | 56.26 Million | 47.15 Million | - | 45.26 Million |
| Research and Development Expenses | 59.33 Million | 58.74 Million | 58.5 Million | 54.7 Million | - | 45.51 Million |
| Other Expenses | - | 500 Thousand | - | - | - | - |
| Cost and Expenses | 135.94 Million | 128.2 Million | 117.3 Million | 103.73 Million | 375.09 Million | 92.42 Million |
| Operating Income | 46.59 Million | 35.59 Million | 29.5 Million | 31.66 Million | 107.28 Million | 31.17 Million |
| Interest Expense | - | - | - | 3.58 Million | - | - |
| Income Tax Expense | 5.73 Million | 6.1 Million | 7.23 Million | 5.45 Million | 18.41 Million | 5 Million |
| Earnings before Tax | 52.94 Million | 41.59 Million | 34.99 Million | 36.8 Million | 124.55 Million | 36.38 Million |
| Net Income | 47.21 Million | 35.48 Million | 27.76 Million | 31.35 Million | 106.14 Million | 31.37 Million |
| Earnings Per Share Basic | 0.45 | 0.34 | 0.27 | 0.30 | - | 0.31 |
| Earnings Per Share Diluted | 0.41 | 0.32 | 0.25 | 0.28 | - | 0.28 |
| Weighted Average Shares Outstanding | 103.37 Million | 103.11 Million | 102.79 Million | 102.45 Million | 103.56 Million | 102.01 Million |
| Weighted Average Shares Outstanding (Diluted) | 113.72 Million | 111.24 Million | 109.91 Million | 110.88 Million | 111.74 Million | 111.09 Million |
| Gross Margin | 0.98 | 0.98 | 0.98 | 0.99 | 0.99 | 0.99 |
| EBIT Margin | 0.26 | 0.22 | 0.20 | 0.24 | - | 0.25 |
| Profit Margin | 0.26 | 0.22 | 0.19 | 0.23 | 0.22 | 0.25 |
| EBITDA | 47.09 Million | 35.84 Million | 29.62 Million | 32.29 Million | - | 31.34 Million |
| Earnings Before Tax Margin | 0.26 | 0.22 | 0.20 | 0.23 | 0.22 | 0.25 |
VIKASPROP
3022
6515
GENUSPRIME
8480
0RTK